D printing is a good option for bioreactor production. The flexibility of the approach outweighs concerns about higher costs.
Developing a new therapeutic molecule is a complex and expensive process with a high risk of failure at each step. Research suggests that aggregate costs per commercialized drug (including failures) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results